Navigation Links
Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
Date:7/9/2010

LAIYANG, China, July 9 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (Nasdaq: JGBO) (the "Company" or "Jiangbo"), today announced that its management will present at the Global Hunter Securities China Investment Conference, which takes place July 11-13, 2010 at the St. Regis Hotel in San Francisco.

Presentation Time: 7:30 a.m. PT, Monday, July 12, 2010

Location: Presentation Room 2, St. Regis Hotel, San Francisco

This event features approximately 100 China-based companies, most of which have shares that trade on U.S. exchanges. Companies from various sectors will make presentations to institutional investors during the conference, which serves as a forum for management teams to showcase their investment rationales, growth plans, current outlooks and positioning in China's growing marketplace. For more information about the conference and registration, please visit http://www.ghsecurities.com .

About Global Hunter Securities

Global Hunter Securities, LLC is a full service investment bank focusing on middle market corporate and institutional clients around the world. The firm provides insightful research, innovative capital raising and financial advisory and restructuring services supported by a sales and trading staff with world-wide reach. Global Hunter has offices in San Francisco, Los Angeles, New York, Houston, New Orleans, Newport Beach and Hong Kong, as well as a strong presence and reputation in mainland China. For more information about Global Hunter, please visit http://www.ghsecurities.com .

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com ).

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Tel:   +1-954-903-9378 x2
     Email: elsasung@jiangbo.com
     Web:   http:// www.jiangbopharma.com

    CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com


'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
2. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
3. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
4. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
5. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
6. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
7. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
8. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
9. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
10. ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
11. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 31, 2016 , ... More than 80 representatives of the Hepatitis B ... Cancer Foundation held an event on National Hepatitis Testing Day outside of Philadelphia City ... the leading cause of liver cancer. , Foundation leaders and the citywide coalition they ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... mix of advanced Artificial Intelligence (AI) and the latest in Clinical Patient ... center is integrating predictive analytic outputs directly into the clinical workflow. These insights ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only drive service to the ... whole. On June 2, Northbound CEO Mike Neatherton and COO Paul Alexander will be ... opening plenary on “Leadership: The Journey to Authenticity” with Onsite Workshops CEO Miles Adcock ...
(Date:5/31/2016)... ... 31, 2016 , ... In his latest video, renowned AstroNumerologist ... humans. Using presidential candidate Donald Trump as an example, Kalsi describes the way ... not about adding numbers up,” says Kalsi. “It is about looking at each ...
(Date:5/31/2016)... ... 31, 2016 , ... TeaZa® Energy, LLC announces the launch of ... No Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers ... , The new flavor is best described as a juicy, taste bud takeover. ...
Breaking Medicine News(10 mins):